Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Yen Near 40-Year Low as USD/JPY Approaches Key 162 Level, Raising Intervention Concerns
Singapore Inflation Stays Muted in May as Core CPI Misses Forecasts Ahead of MAS Review
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results
South Korea Remains MSCI Emerging Market Despite Reform Progress
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices
US Dollar Climbs to One-Year High as Fed Rate Hike Expectations Surge
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 



